DK2459197T3 - Forbindelser til reduktion af beta-amyloidproduktion - Google Patents

Forbindelser til reduktion af beta-amyloidproduktion Download PDF

Info

Publication number
DK2459197T3
DK2459197T3 DK10747095.7T DK10747095T DK2459197T3 DK 2459197 T3 DK2459197 T3 DK 2459197T3 DK 10747095 T DK10747095 T DK 10747095T DK 2459197 T3 DK2459197 T3 DK 2459197T3
Authority
DK
Denmark
Prior art keywords
dihydro
chloro
phenyl
pyrimidine
imidazol
Prior art date
Application number
DK10747095.7T
Other languages
English (en)
Inventor
Kenneth M Boy
Jason M Guernon
John E Macor
Richard E Olson
Jianliang Shi
Iii Lorin A Thompson
Yong-Jin Wu
Li Xu
Yunhui Zhang
Dmitry S Zuev
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2459197T3 publication Critical patent/DK2459197T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (19)

  1. FORBINDELSER TIL REDUKTION AF BETA-AMYLOIDPRODUKTION PATENTKRAV
    1. Forbindelse med formlen (I)
    (I), eller et farmaceutisk acceptabelt salt deraf, hvor A er en fem- eller seks-leddet heteroaromatisk ring, der indeholder fra et til tre heteroatomer, der er uafhgengigt udvalgt fra nitrogen, oxygen og svovl; bvor den heteroaromatiske ring eventuelt er substitueret med én eller to grupper, der er udvalgt fra halo, haloCi_6-alkyl, hydroxy, amino, Ci.6-alkoxy, og Ci^-alkyl; B er udvalgt fra phenyl og pyridinyl, hvor phenyl og pyridinyl eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra Ci_6-alkoxy, Ci_6-alkyl, Ci.3-alkylamino-C].6-alkoxy, cyano, Ci_3-dialkylamino-Ci_6-alkoxy, halo, haloCK6-alkoxy, haloCi.6-alkyl, hydroxy, methylamino og amino; D er udvalgt fra
    betegner udgangsmolekylets fastgorelsespunla til nitrogenatomet;
    betegner fastgorelsespunktet til ’E'-delen; Ra er udvalgt fra hydrogen, Ci_6-alkyl, C2_6-alkenyl og hydroxy; Rb er -NRxRy, hvor Rx og Ry uafhcengigt er udvalgt fra hydrogen, CM-alkoxy, Ci_4-alkoxyCi4-alkyl, Ci^-alkoxycarbonyl, Ci_6-alkyl, C3.7-cycloalkyl, (C3.7-cycloalkyl)Ci.4-alkyl, hydroxyCi_4-alkyl, og trideuteromethyl, hvor alkyldelen af (C3.7-cycloalkyl)Ci_4-alkyl eventuelt kan substitueres med en Ci_4-alkoxygruppe; eller, Rx og Ry, sammen med nitrogenatomet, til hvilket de er bundet, danner en ñre- til syv-leddet monocyklisk eller bicyklisk ring, der eventuelt indeholder en dobbeltbinding og eventuelt indeholder et yderligere heteroatom, der er udvalgt fra O, NRZ og S; hvor Rz er udvalgt fra hydrogen, Ci.6-alkyl, og Ci. 4-alkoxycarbonyl; og hvor ringen eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra Ci_6-alkoxy, Ci_6-alkyl, halo, haloCi_4-alkyl, hydroxy, -NRfRE, oxo, spirocyklisk dioxolanyl; hvor Rf og Rs uafhcengigt er udvalgt fra hydrogen, Ci_4-alkoxycarbonyl og Ci_6-alkyl; R° er udvalgt fra hydrogen, Ci_4-alkylsulfonyl, Ci_4-alkylsulfonylamido, amino, Ci_6-alkylamino, Ci_6-dialkylamino, C3.7-cycloalkylamino, hydroxy og Ci_4-alkoxy; Rd er udvalgt fra hydrogen, Ci_6-alkyl, Ci_4-alkoxyCi_4-alkylcarbonyl, Ci_6-alkoxycarbonyl, C14-alkylcarbonyl, Ci_6-alkylsulfonyl, C3_7-cycloalkylsulfonyl, C3.7-cycloalkylcarbonyl, Ci4-dialkylaminoCi4-alkylcarbonyl, og haloCi_4-alkyl, hvor alkyldelen af alkoxycarbonyl, alkylcarbonyl og alkylsulfonyl eventuelt er substitueret med en substituent, der er udvalgt fra Ci^-dialkylamino, og Ci^-alkoxy; og E er udvalgt fra Cu,-al kyl, C4.6-cycloalkyl, (C4.7-cycloal kyl)C 14-al kyl, benzyl, phenyl, og en fem-til seks-leddet heteroaromatisk ring, der indeholder ét eller to nitrogenatomer, hvor phenyl, phenyldelen af benzyl og den heteroaromatiske ring hver eventuelt er substitueret med en, to eller tre substituenter, der er uafhcengigt udvalgt fra Ci.6-alkyl, Ci_6-alkoxy, cyano, halo, halo, Ci^-alkoxy og haloCi_6-alkyl.
  2. 2. Forbindelse ifolge krav 1, eller et farmaceutisk acceptabelt salt deraf, hvor A er en fem-leddet heteroaromatisk ring, der indeholder fra et til tre nitrogenatomer; hvor den heteroaromatiske ring eventuelt er substitueret med en gruppe, der er udvalgt fra halo og Cu,-alkyl.
  3. 3. Forbindelse ifolge krav 2, eller et farmaceutisk acceptabelt salt deraf, hvor B er udvalgt fra phenyl og pyridinyl, hvor phenyl og pyridinyl eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra Cj.6-alkoxy og halo.
  4. 4. Forbindelse ifolge krav 3, eller et farmaceutisk acceptabelt salt deraf, hvor E er phenyl eventuelt substitueret med én, to eller tre substituenter, der er uafhaengigt udvalgt fra Ci^-alkyl, Ci.6-alkoxy, cyano, halo, haloCi_6-alkoxy og haloCi.6-alkyl.
  5. 5. Forbindelse ifolge krav 4, eller et farmaceutisk acceptabelt salt deraf, hvor D er udvalgt fra
  6. 6. Forbindelse ifolge krav 5, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry uafhaengigt er udvalgt fra hydrogen, C14-al koxyC ] 4-alkyl, Ci_6-alkyl, C3_7-cycloalkyl, hydroxyC'14-alkyl, og trideuteromethyl, hvor alkyldelen af (C3_7-cycloalkyl)Ci4-alkyl eventuelt kan substitueres med en C1 _4~'d\ koxygruppc.
  7. 7. Forbindelse ifolge krav 5, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry, sammen med nitrogenatomet, til bvilket de er bundet, danner en fire- til syv-leddet monocyklisk eller bicyklisk ring, der eventuelt indebolder et yderligere heteroatom, der er udvalgt fra O og NRZ; hvor Rz er udvalgt fra Ci^-alkyl, og CM-alkoxycarbonyl; og hvor ringen eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra Ci^-alkoxy, C'i.6-alkyl, halo, haloCM-alkyl, hydroxy, -NRfRg, oxo og spirocyklus dioxolanyl; hvor Rf og Rs uafhaengigt er udvalgt fra hydrogen, C i _4-alkoxycarbonyl og Cj.e-alkyl.
  8. 8. Forbindelse i fulge krav 4, eller et farmaceutisk acceptabelt salt deraf, hvor D er udvalgt fra
  9. 9. Forbindelse ifolge krav 8, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry uafhaengigt er udvalgt fra hydrogen, Ci^-alkoxyCi^-alkyl, Ci.6-alkyl, C3.7-cycloalkyl, hydroxyCi^-alkyl, og trideuteromethyl, hvor alkyldelen af (C3.7-cycloalkyl)CM-alkyl eventuelt kan substitueres med en Ci_4-alkoxygruppe.
  10. 10. Forbindelse ifolge krav 8, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry, sammen med nitrogenatomet, til hvilket de er bundet, danner en fire- til syv-leddet monocyklisk eller bicyklisk ring, der eventuelt indeholder et yderligere heteroatom, der er udvalgt fra O og NRZ; hvor Rz er udvalgt fra C'i_6-alkyl, og Ci^-alkoxycarbonyl; og hvor ringen eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra Ci_6-alkoxy, Ci_6-alkyl, halo, haloCM-alkyl, hydroxy, -NRfRg, oxo og spirocyklus dioxolanyl; hvor Rf og Rs uafhaengigt er udvalgt fra hydrogen, Ci_4-alkoxycarbonyl og Ci_6-alkyl.
  11. 11. Forbindelse ifolge krav 4, eller et farmaceutisk acceptabelt salt deraf, hvor D er udvalgt fra
  12. 12. Forbindelse ifolge krav 11, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry uafhaengigt er udvalgt fra hydrogen, CM-alkoxyCM-alkyl, CV6-alkyl, C3.7-cycloalkyl, hydroxyC,^-alkyl, og trideuteromethyl, hvor alkyldelen af (C3.7-cycloalkyl)CM-alkyl eventuelt kan substitueres med en Cj^-alkoxygruppe.
  13. 13. Forbindelse ifolge krav 11, eller et farmaceutisk acceptabelt salt deraf, hvor Rb er -NRxRy, hvor Rx og Ry, sammen med det nitrogenatom, til hvilket de er bundet, danner en fire- til syv-leddet monocyklisk eller bicyklisk ring, der eventuelt indeholder et yderligere heteroatom, der er udvalgt fra O og NRZ; hvor Rz er udvalgt fra Ci.6-alkyl, og C,^-alkoxycarbonyl; og hvor ringen eventuelt er substitueret med én eller to substituenter, der er uafhaengigt udvalgt fra C1.6-alkoxy, Ci_6-alkyl, halo, haloCM-alkyl, hydroxy, -NRfRs, oxo og spirocyklus dioxolanyl; hvor Rf og Rg uafhaengigt er udvalgt fra hydrogen, C^-al koxycarbonyl og Ci.6-alkyl.
  14. 14. Forbindelse if0lge krav 1 udvalgt fra N2-(3-methoxy-4-(3-methyl-1 Η-1,2,4-triazol-1-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-ñuor-4-(3-methyl-1H-1,2,4-triazol-l-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(3 -ñuor-4-(5 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3 -ñuor-4-(5 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4,N4-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4,N4-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4,N4-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-N4-methyl-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-N4-methyl-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 4-(Azetidin-1 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d] pyrimidin-2 - amin; (S) -4-(Azetidin-1 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (R) -4-(Azetidin-1 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-cyclopropyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-cyclobutyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-isopropyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-N4 -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(2-ñuor-5-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-fluorphenyl)-N4-methyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(6-(4-chlor-lH-imidazol-l-yl)-5-methoxypyridin-3-yl)-7-(4-fluorphenyl)-N4-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-7-(4-ñuorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-(3,3 -diñuorazetidin-1 -yl)-N-(3 -fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-(3,3 -diñuorazetidin-1 -yl)-N-(3 -ñuor-4-(5-methyl-lH-l ,2,4-triazol-1 -yl)phenyl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-(3,3 -diñuorazetidin-1 -yl)-N-(3 -fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(3 -chlor-1 Η-1,2,4-triazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(3 -chlor-1 Η-1,2,4-triazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(3-chlor-lH-l,2,4-triazol-l-yl)-3-methoxyphenyl)-4-(3,3-difluorazetidin-l-yl)-7-(4- fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(4-(4-chlor-lH-imidazol-l-yl)-3- methoxyphenyl)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(4-(4-chlor-lH-imidazol-l-yl)-3- methoxyphenyl)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-(( 1 S,4S)-2-oxa-5-azabicyclo [2.2.1 ]heptan-5 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-(2-methylpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(2-methylpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(2-methylpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(2-methylpynOlidiii-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-fluorplienyl)-4-(2-metliylpyTrolidiii-l- yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(2-metliylpyrrolidm-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin, N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4- fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4- fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4- fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; l-(2-(4-(4-cMor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-(4-fluorphenyl)-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-yl)-4-methylpiperidin-4-ol; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(2-ethylpyrrolidin-1 -yl)-7-(4-ñuorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(2-ethylpyrrolidin-1 -yl)-7-(4-fluorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(2-ethylpyrrolidin-1 -yl)-7-(4-fluorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(2-ethylpyrrolidin-1 -yl)-7-(4-fluorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-(2-ethylpyrrolidin-l-yl)-7-(4-ñuorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -metlioxyplienyl)-4-(2-ethylpyrrolidiii-1 -yl)-7-(4-fluorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 4-(4-amino-4-methylpiperidin-l-yl)-N-(4-(4-chlor-lH-imidazol-l-yl)-3-metlioxyplienyl)-7-(4- fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-fluorphenyl)-N4-methyl-6,7-diliydro- 5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3 -ñuor-4-(5 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-2,4-diamin; 1-(2-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3 -(triñuormethyl)pyrrolidin-3 -ol; 1 -(2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenylamino)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3 -(triñuormethyl)pyrrolidin-3 -ol; 1-(2-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3 -(triñuormethyl)pyrrolidin-3 -ol; 1-(2-(4-(4-chlor-1 H-imidazol-1-yl)-3-metho xyphenylamino)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3 -(triñuormethyl)pyrrolidin-3 -ol; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -(dimethylamino)pyrrolidin-1 -yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -(dimethylamino)pyrrolidin-1 -yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -(dimethylamino)pyrrolidin-1 -yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-4-(4-methylpiperazin-1 -yl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-(4-methylpiperazin-1 -yl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-(4-methylpiperazin-1 -yl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-(piperazin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-4-(3-(methylamino)pyrrolidin-l-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-4-(3-(methylamino)azetidin-l-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -(dimethylamino)azetidin-1 -yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(3 -fluor-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-((R)-3 -ñuorpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-((R)-3 -ñuorpyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin); N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(4,4-difluorpiperidin-1 -yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(4-fluor-5,6-dihydropyridin-1 (2H)-yl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(3-(triñuormethyl)pyrrolidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-(3-ethoxypropyl)-7-(4-fluorphenyl)-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 3-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ylamino)propan-1 -ol; 7-(4-fluorphenyl)-N2-(3-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-l H-imidazol- l-yl)-3 -methoxyphenyl)-N4-( 1-cyc lopropyl-2-methoxyethyl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-N4,N4-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-N4,N4-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-N4,N4-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-N4-trideuteromethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-fluorphenyl)-N4-((R)-1 -methoxybutan-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-N4-((R)-1-cyclopropylethyl)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-N4-((S)- 1-cyc lopropylethy 1)-7-(4-ñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-phenyl-7,8-dihydro-5H-pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imiazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-phenyl-7,8-dihydro-5H-pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imiazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-phenyl-7,8-dihydro-5H-pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-N4-methyl-8-phenyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-N4-methyl-8 -phenyl-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-N4-methyl-8 -phenyl-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4,N4-dimethyl-8-phenyl-7,8-dihydro-5H-pyrano [4,3-d] pyrimidin-2,4 -diamin; (S) -N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4,N4-dimethyl-8-phenyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4,N4-dimethyl-8-phenyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-ñuorphenyl)-N2-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-8-(4-fluorphenyl)-N2-(3-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-7,8-dihydro-5H-pyrano [4,3-d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((R)-3-fluorpyrrolidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-ñuorphenyl)-4-((R)-3-ñuorpyrrolidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((S)-3-fluorpyrrolidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N4-ethyl-N2-(3 -ñuor-4-(5-methyl- 1H-1,2,4-triazol-1 -yl)phenyl)-8-(4-fluorphenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-8 -(4-fluorphenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-8 -(4-fluorphenyl)- 7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4-methyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4-methyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4-methyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-4-(3,3-difluorazetidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N-(4-(4-chh3r-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-4-(3,3-difluorazetidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N-(4-(4-chh3r-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-chlorphenyl)-4-(3,3-difluorazetidin-l-yl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; 8-(4-chlorphenyl)-N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 8-(4-chlorphenyl)-N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4,N4-dimethyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 8-(4-chlorphenyl)-N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4,N4-dimethyl-7,8- dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-4-(3,3-difluorazetidin-1-yl)-N-(3-fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl) -7,8 -dihydro - 5 H-pyrano [4,3-d] pyrimidin-2 - amin; 8-(4-chlorphenyl)-N2-(3 -ñuor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(4-methyl-1 H-imidazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(4-methyl-1 H-imidazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(4-methyl-1 H-imidazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 8-(4-chlorphenyl)-N2-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 8-(4-bromphenyl)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; 8-(4-bromphenyl)-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-((S)-2-methylpyrrolidin-1 -yl)-5,7-dihydrofuro[3,4-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-7-(4-ñuorphenyl)-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-7-(4-ñuorphenyl)-5,7- dihydrofuro[3,4-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-7-(4-ñuorphenyl)-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-1 -yl)- 5,7 -dihydro furo [ 3,4 -d] pyrimidin-2 - amin; N-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-((S)-3-ñuorpyrrolidin-1 -yl)- 5,7 -dihydro furo [ 3,4 -d] pyrimidin-2 - amin; N4-ethyl-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-5,7- dihydrofuro[3,4-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N4-ethyl-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-N4-methyl-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-N4-methyl-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-7-(4-ñuorphenyl)-5,7 -dihydro furo [ 3,4 -d] pyrimidin-2 -amin; N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-N4-((R)-l-cyclopropylethyl)-7-(4-ñuorphenyl)-5,7-dihydrofuro[3,4-d]pyrimidin-2,4-diamin; N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7-(4-ñuorphenyl)-N4-methyl-5,7-dihydro furo [ 3,4 -d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-ñuorphenyl)-4-((R)-3 -ñuorpyrrolidin-1 -yl)- 5,7 -dihydro furo [ 3,4 -d] pyrimidin-2 - amin; N-(4-(4-chlor-l H-imidazol-1-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4-ñuorphenyl)-5,7-dihydrofuro[3,4-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-phenyl-6,8-dihydro-5H-pyrano [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(3-ñuor-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-8-phenyl-6,8-dihydro-5H-pyrano [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(3-ñuor-4-(5-methyl- 1H-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-8-phenyl-6,8-dihydro-5H-pyrano [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-6,8-dihydro-5H-pyrano [ 3,4 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl-6,8-dihydro -5 H -pyrano [ 3,4 -d] pyrimidin-2,4 -diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((R)-3-fluorpyrrolidin-l-yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((R)-3-fluorpyrrolidin-l-yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-l- yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((S)-3-fluorpyrrolidin-l- yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-chlorphenyl)-N4,N4-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-chlorphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-chlorphenyl)-N4-methyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-7-(4-chlorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-7-(4-chlorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,4-diñuorphenyl)-N4,N4-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,4-diñuorphenyl)-N4,N4-dimethyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,4-diñuorphenyl)-N4,N4-dimethyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,4-difluorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(3,4-diñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,4-diñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-(4-(trifluormethoxy)phenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-7-(4- (triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-7-(4-(trifluormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-7-(4-(trifluormethoxy)phenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-7-(4-(trifluormethoxy)phenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-4-(3,3-diñuorazetidin-l -yl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (S) -N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-(3,3-difluorazetidin-l-yl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (R) -N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4,N4-dimethyl-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-N4,N4-dimethyl-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R) -N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4,N4-dimethyl-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 4-(Azetidin-1 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (S) -4-(Azetidin-l-yl)-N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (R) -4-(Azetidin-1 -yl)-N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(4-(triñuormethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(3,5-diñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-7-(3,4,5-triñuorphenyl)-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-7-(3,4,5-triñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-(3,4,5-triñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3 -fluor-4-(5 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl-7-(3,4,5-trifluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(6-(4-chlor-1 H-imidazol-1 -yl)-5 -methoxypyridin-3 -yl)-N4-methyl-7-(3,4,5-trifluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(3 -chlor-1 Η-1,2,4-triazol-1 -yl)-3 -methoxyphenyl)-N4-methyl-7-(3,4,5-trifluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-4-(3,3-diñuorpyrrolidin-l-yl)-7-(3,4,5-triñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (S)-N-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluorpyrrolidin-1-yl)-7-(3,4,5-trifluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; (R) -N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorpyrrolidin-1 -yl)-7-(3,4,5-triñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-4-(3,3-diñuorazetidin-l -yl)-7-(3,4,5-triñuorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(2,4-difluorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S) -N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(2,4-diñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-7-(2,4-diñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-N4-ethyl-7-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-7-allyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(3,5-diñuorphenyl)-N4-ethyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(3,4-diñuorphenyl)-N4-ethyl-7,8-dihydro- 5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-(3,3-diñuorazetidin-l-yl)-8- (3,4- diñuorphenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(3,4-diñuorphenyl)-N4-methyl-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; 8-(3,4-diñuorphenyl)-N4-ethyl-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-((R)-l-cyclopropylethyl)-8-(4- (triñuormethyl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-(trifluormethyl)plienyl)-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; N4-ethyl-N2-(3-ñuor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-8-(4-(triñuormethyl)phenyl)-7,8-dihydro -5 H -pyrano [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-(4-(trifluormethyl)phenyl)-7,8-dihydro -5 H -pyrano [4,3-d] pyrimidin-2,4 -diamin; 4-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-7,8-dihydro-5H-pyrano [4,3-d] pyrimidin- 8 -yl)benzonitril; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-8-(4-(trifluormethoxy)phenyl)- 7.8- dihydro-5H-pyrano[4,3-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-((R)-3 -ñuorpyrrolidin-1 -yl)-8-(4-(triñuormethoxy)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amin; N2-(4-(4-chlor- lH-imidazol-1 -yl)-3-methoxyphenyl)-N4-ethyl-N4-methyl-8-phenyl-5,6,7,8-tetrahydroquinazolin-2,4-diamin; (S)-N2-(4-(4-chlor- lH-imidazol-1 -yl)-3-methoxyphenyl)-N4-ethyl-N4-methyl-8-phenyl-5,6,7,8-tetrahydroquinazolin-2,4-diamin; (R) -N2-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-N4-ethyl-N4-methyl-8-phenyl-5,6,7,8-tetrahydroquinazolin-2,4-diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-phenyl-5,6,7,8-tetrahydroquinazolin-2- amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl- 5.6.7.8 -tetrahydro quinazolin-2,4 -diamin; N2-(4-(4-chlor-l H-imidazol-1 -yl)-3-methoxyphenyl)-8-(4-ñuorphenyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazolin-2,4-diamin; (S) -N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-N4,N4-dimethyl- 5.6.7.8 -tetrahydro quinazolin-2,4 -diamin; (R)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-N4,N4-dimethyl- 5.6.7.8 -tetrahydro quinazolin-2,4 -diamin; N-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-5,6,7,8-tetrahydroquinazolin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-methyl-6-(methylsulfonyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-6-(cyclopropylsulfonyl)-N4-methyl-8- phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; Methyl 2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylat; (2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(cyclopropyl)methanon; l-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-2-methoxyethanon; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-6-(methylsulfonyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; l-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-2-(dimethylamino)ethanon; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-6-(cyclopropylsulfonyl)-N4-ethyl-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; l-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)ethanon; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-6-(ethylsulfonyl)-8-phenyl-5,6,7,8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3-fluor-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-6-(methylsulfonyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3 -ñuor-4-(5-methyl- 1H-1,2,4-triazol-l -yl)phenyl)-6-(methylsulfonyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; 6-(cyclopropylsulfbnyl)-N2-(3-fluor-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-8- phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; 6-(cyclopropylsulfonyl)-N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-8- phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; cyclopropyl(4-(ethylamino)-2-(3 -ñuor-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenylamino)-8-phenyl- 7.8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanon; cyclopropyl(4-(ethylamino)-2-(3 -ñuor-4-(5 -methyl-1 Η-1,2,4-triazol-1 -yl)phenylamino)-8-phenyl- 7.8- dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanon; N4-ethyl-N2-(3-ñuor-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-8-phenyl-6-(2,2,2-triñuorethyl)- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3 -ñuor-4-(5-methyl- 1H-1,2,4-triazol-l -yl)phenyl)-8-phenyl-6-(2,2,2-trifluorethyl)- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4,N4-dimethyl-6-(methylsulfonyl)-8- phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N2-(3-ñuor-4-(3-methyl- 1H-1,2,4-triazol-1 -yl)phenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N2-(3-ñuor-4-(5-methyl- 1H-1,2,4-triazol-1 -yl)phenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N4-ethyl-N2-(3-ñuor-4-(3-methyl-lH-1,2,4-triazol-l-yl)phenyl)-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N4-ethyl-N2-(3-fluor-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-1 H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-N4-methyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-6- (methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3 -ñuor-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-8-(4-fluorphenyl)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3 -ñuor-4-(5-methyl- 1H-1,2,4-triazol-l-yl)phenyl)-6-(methylsulfonyl)-8-(4-fluorphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-N4,6-diethyl-8-(4-ñuorphenyl)-N4-methyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-8 -(4-fluorphenyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-8 -(4-fluorphenyl)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3,3 -diñuorazetidin-1 -yl)-8 -(4-fluorphenyl)- 5,6,7,8 -tetrahydropyrido [4,3 -d] pyrimidin-2 - amin; N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-N4,6-dimethyl-5,6,7,8-tetrahydropyrido [4,3 -d] pyrimidin-2,4 -diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-6-methyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4,6-dimethyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl- 5.6.7.8- tetrahydropyrido[3,4-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-8-(4-ñuorphenyl)-4-((S)-3-ñuorpyrrolidin-l-yl)-7-(4-methoxybenzyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-7- (methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-l H-imidazol- l-yl)-3-methoxyphenyl)-N4,7-diethyl-8-(4-ñuorphenyl)-5,6,7,8-tetrahydropyrido [ 3,4 -d] pyrimidin-2,4 -diamin; methyl 2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenylamino)-4-(ethylamino)-8-(4- ñuorphenyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-carboxylat; l-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-(4-ñuorphenyl)- 5,6 -dihydropyrido [ 3,4 -d] pyrimidin- 7 (8 H) -yl)ethanon; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphenyl)-N4-methyl-7- (methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2,4-diamin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((R)-3-fluorpyrrolidiii-l- yl)-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-8-(4-fluorphenyl)-4-((R)-3-fluorpyrrolidin-l- yl)-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amin; N2-(4-(4-chlor-l H-imidazol-l-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorphcTiyl)-7-mcthyl- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2,4-diamin; N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-trideuteromethyl-7-phenyl-6,7-dihydro- 5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-trideuteromethyl-7-phenyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-N2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-N4-trideuteromethyl-7-phenyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(methylamino)-8-phenyl-7,8- dihydroquinazolin-8-ol; 2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(methylamino)-8-phenyl-5,6,7,8- tetrahydroquinazolin-8-ol; 2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(dimethylamino)-7-phenyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-7-ol; (6S,7S)-2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(dimethylamino)-7-phenyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-6-ol; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -chlorazetidin-1 -yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -fluorazetidin-1 -yl)-7 -phenyl-6,7 -dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -methoxyazetidin-1 -yl)-7 -phenyl-6,7-dihydro-5 H -cyclopenta[d] pyrimidin-2 -amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyplienyl)-7-plienyl-4-(5,8-dioxa-2-azaspiro[3.4]octan-2- yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; l-(2-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-on; l-(2-(4-(4-chlor-1 H-imidazol-1 -yl)-3-methoxyphenylamino)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylazetidin-3-carbomtril; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-4-(3-ethoxyazetidin-l-yl)-7-(4-fluorphenyl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; N-(4-(4-chlor-l II-imidazol-l-yl)-3-mcthoxyphcnyl)-7-phcnyl-4-(5-oxa-2-azaspiro[3.4]octan-2-yl)- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 1- (2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-(4-fluorphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylazctidin-3-ol; N-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenyl)-4-(3 -fluor-3 -methylazetidin-1 -yl)-7-(4-lluorphcnyl)-6,7-dihydro-5II-cyclopenta[d]pynmidin-2-amin; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-4-(3-methoxy-3-methylazetidin-1 -yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 7-(4-fluorphenyl)-4-(3 -methoxy-3 -methylazetidin-1 -yl)-N-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-l-yl)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; 7- (2,4-difluorphenyl)-N2-(3-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (S)-7-(2,4-difluorphenyl)-N2-(3-methoxy-4-(3-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4-methyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; (R)-7-(2,4-difluorphenyl)-N2-(3-methoxy-4-(3-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4-methyl- 6.7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 6-(2,2-difluorethyl)-N4-ethyl-N2-(3-fluor-4-(5-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; 6-(2,2-difluorethyl)-N4-ethyl-N2-(3-fluor-4-(3-methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-8-phenyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3 -methoxy-4-(4-chlor-1 Η-13 -imidazol-1 -yl)phenyl)-8-phenyl-6-(2,2,2-trifluorethyl)- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; N4-ethyl-N2-(3-methoxy-4-(4-chlor-lH-13-imidazol-l-yl)phenyl)-8-phenyl-6-(2,2-difluorethyl)- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; 8- (4-ñuorphenyl)-N2-(3 -methoxy-4-(3 -methyl-1 Η-1,2,4-triazol-1 -yl)phenyl)-N4,6-dimethyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; 8-(4-fluorphenyl)-N2-(3-methoxy-4-(5-methyl-lH-l,2,4-triazol-l-yl)phenyl)-N4,6-dimethyl- 5.6.7.8- tetrahydropyrido[4,3-d]pyrimidin-2,4-diamin; (±)-2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-5-on; (E)-2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-5-one-0-methyloxim; 2- (4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-ol; N2-(4-(4-chlor-lH -imidazol-1 -yl) - 3 -methoxyphenyl) -N 4 -methyl- 8 -phenyl- 5,6,7,8-tetrahydroquinazolin-2,4-diamin; l-(2-methoxy-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)-1 H-imidazol-4-carbonitril; N-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenyl)-7-phenyl-4-(l,4-dioxa-7-azaspiro[4.4]nonan- 7-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amin; l-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-on; N2-(4-(4-(difluormethyl)-lH-imidazol-l-yl)-3-methoxyphenyl)-7-(4-fluorphenyl)-N4-methyl-6,7- dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3 -methoxy-4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N-(2-(4-(4-chlor-1 H-imidazol-1 -yl)-3 -methoxyphenylamino)-7 -phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-methylmethansulfonamid; N-(2-(4-(4-chlor-l II-imidazol-1 -yl)-3-mcthoxyphcnylamino)-7-phcnyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-methansulfonamid; N-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-yl)-N-methylacetamid; N-(2-(4-(4-chlor-lH-imidazol-l-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-4-yl)-N-acetamid; N2-(4-(4-chlor-1 H-imidazol-1 -yl)-3-mcthoxyphenyl)-N4-(5-isopropyl-2-methylphcnyl)-7-phcnyl- 6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-methoxy-4-(2-methylpyridin-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; N2-(3-methoxy-4-(pyridin-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin og N2-(3-methoxy-4-(pyridin-3-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; eller et farmaceutisk acceptabelt salt deraf.
  15. 15. Forbindelse udvalgt fra 4-(8-(4-ñuorphenyl)-4-(methylamino)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidin-2-ylamino)benzonitril; 4-(4-(5-isopropyl-2-methylphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)benzonitril; N4-methyl-N2-(2-mcthylpyndm-4-yl)-7-phcnyl-6,7-dihydro-5II-cyclopcnta[d]pyrimidin-2,4- diamin; N2-(3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyriinidin-2,4-diamÍQ; N2-(4-ñuorphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(3,5-diñuorphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N2-(4-chlor-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N2-(4-brom-2-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N2-(4-fluor-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N4-methyl-7-phenyl-N2-(pyrimidin-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diainin; N4-methyl-7-phenyl-N2-(pyridin-4-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; 4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamÍQo)benzonitril; 4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamÍQo)benzonitril; 4-(4-(methylamino)-7-pbenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamÍQo)benzonitril; 2-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitril; 4- (4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-l-naphthonitrile; 5- (4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)picolinomtril; 2-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)phenyl)acetonitril; 2- (4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-lH- benzo[d]imidazole-5-carbonitril; 3- (4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitril; N2-(4-tert-butylphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N4-methyl-N2-(4-(methylsulfonyl)phenyl)-7-phenyl-6,7-dibydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N4-metbyl-7-phenyl-N2-(4-(trifluormethoxy)pbenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; 4- (4-(metbylamino)-7-pbenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)pbthalonitril; 4- (4-(metbylamino)-7-pbenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-2-(trifluormetbyl)benzonitril; N4-metbyl-7-phenyl-N2-(4-(trifluormethyl)pbenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; 5- (4-(metbylamino)-7-pbenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-2,3-dihydro- lH-inden-l-on; 2-(4-(metbylamino)-7-pbenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-lH-imidazol- 4,5-dicarbonitril; 2-brom-5-(4-(metbylamino)-7-pbenyl-6,7-dibydro-5H-cyclopenta[d]pyrimidin-2- ylamino)benzonitril; N,N-dimethyl-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)benzamid; l-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)phenyl)cyclopentanecarbonitril; N4-methyl-7-phenyl-N2-(l,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H- cyclopenta[d]pyrimidin-2,4-diamin; 4-(4-(methylamino)-7-phenyl-6,7-dihydro-5FI-cyclopenta[d]pyrimidin-2-ylammo)-2- (trifluormethoxy)benzonitril; l-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)phenyl)cyclopropancarbonitril; l-(2-methoxy-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)phenylamino)cyclopropancarbonitril; N4-methyl-N2-(2-methyl-lH-indol-5-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N2-(benzofuran-5-yl)-N4-methyl-7-phenyl-6,7-dihydro-5FI-cyclopenta[d]pyrimidin-2,4-diamin; N2-(lH-indol-5-yl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4-diamin; N4-methyl-N2-(2-methylbenzo[d]oxazol-6-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin- 2.4- diamin; N2-(lH-benzo[d]imidazol-6-yl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N4-methyl-N2-( 1 -methyl-1 H-indol-5-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; N4-methyl-N2-(2-methylbenzo[d]thiazol-6-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin- 2.4- diamin; N2-(4-brom-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5F[-cyclopenta[d]pyrimidin-2,4- diamin; l-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2- ylamino)phenyl)ethanon; N2-(4-cyclopropylphenyl)-7-(4-ñuorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin- 2.4- diamin; N2-(4-ethynylphenyl)-7-(4-fluorphenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2,4- diamin; 7-(4-fluorphenyl)-N4-methyl-N2-(4-(prop-l-ynyl)phenyl)-6,7-dihydro-5H-cyclopenta[d] pyrimidin-2,4 -diamin eller et farmaceutisk acceptabelt salt deraf.
  16. 16. Farmaceutisk sammensastning, der omfatter en terapeutisk effektiv masngde af en forbindelse if0lge et hvilket som helst af kravene 1 til 15, eller et farmaceutisk acceptabelt salt deraf, i forbindelse med en farmaceutisk acceptabel basrer eller fortynder.
  17. 17. Forbindelse ifolge et hvilket som helst af kravene 1 til 15, eller et farmaceutisk acceptabelt salt deraf til anvendelse i en fremgangsmáde til behandling af sygdomme, der reagerer pá reduktionen af β-amyloidpeptidfremstilling i et pattedyr med behov derfor, hvor sygdommen er udvalgt fra Alzheimers sygdom (AD), Downs Syndrom, let kognitiv svaekkelse (MCI), cerebral amyloid angiopati (CAA), Lewy body demens (DLB), amyotrofisk lateral sklerose (ALS-D), inklusionslegeme-myositis (IBM) og aldersrelateret makuladegeneration.
  18. 18. Forbindelse til anvendelse ifolge krav 17, hvor forbindelsen er udvalgt fra Alzheimers sygdom og Downs Syndrom.
  19. 19. Forbindelse til anvendelse i fulge krav 18, hvor sygdommen er Alzheimers sygdom.
DK10747095.7T 2009-07-31 2010-07-28 Forbindelser til reduktion af beta-amyloidproduktion DK2459197T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23020209P 2009-07-31 2009-07-31
US32420110P 2010-04-14 2010-04-14
PCT/US2010/043487 WO2011014535A1 (en) 2009-07-31 2010-07-28 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
DK2459197T3 true DK2459197T3 (da) 2016-01-25

Family

ID=43066942

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10747095.7T DK2459197T3 (da) 2009-07-31 2010-07-28 Forbindelser til reduktion af beta-amyloidproduktion

Country Status (29)

Country Link
US (4) US8486952B2 (da)
EP (1) EP2459197B1 (da)
JP (1) JP5680082B2 (da)
KR (1) KR20140015126A (da)
CN (1) CN102548557B (da)
AR (1) AR077434A1 (da)
AU (1) AU2010279019B2 (da)
BR (1) BR112012002270A2 (da)
CA (1) CA2766515A1 (da)
CO (1) CO6430430A2 (da)
DK (1) DK2459197T3 (da)
EA (1) EA020322B1 (da)
ES (1) ES2554327T3 (da)
HK (1) HK1164732A1 (da)
HR (1) HRP20151133T1 (da)
HU (1) HUE026705T2 (da)
IL (1) IL217173A (da)
MX (1) MX2012000973A (da)
MY (1) MY156274A (da)
NZ (1) NZ597701A (da)
PE (1) PE20120897A1 (da)
PL (1) PL2459197T3 (da)
PT (1) PT2459197E (da)
SG (1) SG177526A1 (da)
SI (1) SI2459197T1 (da)
SM (1) SMT201600011B (da)
TW (1) TWI468402B (da)
WO (1) WO2011014535A1 (da)
ZA (1) ZA201200409B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008770B8 (pt) * 2009-02-27 2018-07-31 Dow Agrosciences Llc n-alcóxiamidas de 6-(fenila substituída)-4-aminopicolinatos e 2-(fenila substituída)-6-amino-4 pirimidinacarboxilatos, seus processos de produção, composição herbicida, bem como métodos de controle de vegetação indesejável
MX2013002511A (es) 2010-09-02 2013-07-29 Takeda Pharmaceutical Triazoles fusionados para el tratamiento o profilaxis de daño cognitivo moderado.
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
TW201309655A (zh) * 2011-01-28 2013-03-01 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US9422250B2 (en) 2011-04-08 2016-08-23 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US9206195B2 (en) 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
PT2776439T (pt) 2011-11-09 2018-11-02 Janssen Sciences Ireland Uc Derivados de purina para o tratamento de infeções virais
BR112014019699B1 (pt) * 2012-02-08 2021-12-07 Janssen Sciences Ireland Uc Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
AU2013288600B2 (en) 2012-07-13 2017-06-29 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
KR102217111B1 (ko) 2012-10-10 2021-02-18 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
NZ706226A (en) 2012-11-16 2019-09-27 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6072308B2 (ja) 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉｉ
WO2014127815A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
EA202090547A3 (ru) 2013-03-29 2020-12-30 Янссен Сайенсиз Айрлэнд Юси Макроциклические деаза-оксипурины для лечения вирусных инфекций
CN109776525B (zh) 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
ES2657283T3 (es) 2013-05-24 2018-03-02 Janssen Sciences Ireland Uc Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
EP3004081B1 (en) 2013-06-04 2017-11-15 Acturum Real Estate AB Triazole compounds and their use as gamma secretase modulators
ES2701810T3 (es) 2013-06-04 2019-02-26 Acturum Real Estate Ab Compuestos de triazol y su uso como moduladores de gamma-secretasa
WO2014195323A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Pyrimidine compounds and their use as gamma secretase modulators
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
SG10201803331PA (en) 2013-06-27 2018-06-28 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112016001570B1 (pt) 2013-07-30 2020-12-15 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas e composição farmacêutica que os compreende para o tratamento de infecções virais
KR101861942B1 (ko) * 2014-01-20 2018-06-29 에프. 호프만-라 로슈 아게 신경 발생을 자극할 수 있는 n-페닐-락탐 유도체 및 이의 신경 장애 치료에서의 용도
EP3126355A1 (en) * 2014-04-02 2017-02-08 Bristol-Myers Squibb Company Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production
CN105272975B (zh) * 2014-06-10 2019-03-26 中国科学院上海药物研究所 一类具有1,2,4-恶二唑片段结构的吲哚生物碱及其制备方法和用途
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
CN106366093B (zh) * 2015-07-21 2020-08-18 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
AU2016343980A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit Mnk1 and Mnk2
KR20180070695A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
AU2017335205B2 (en) 2016-09-29 2021-11-04 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
SG11201907356SA (en) 2017-02-14 2019-09-27 Effector Therapeutics Inc Piperidine-substituted mnk inhibitors and methods related thereto
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111315739B (zh) * 2017-11-27 2023-12-05 豪夫迈·罗氏有限公司 嘧啶衍生物
RU2020130837A (ru) 2018-02-21 2022-03-21 ЭйАй ТЕРАПЬЮТИКС, ИНК. Комбинационная терапия апилимодом и глутаматергическими агентами
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. CRYSTALLINE FORMS OF MNK INHIBITORS
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100355750C (zh) * 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
ATE326462T1 (de) * 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
PE20090957A1 (es) * 2007-08-06 2009-07-13 Schering Corp Moduladores de gamma secretasa
AR068636A1 (es) * 2007-09-28 2009-11-25 Schering Corp Moduladores de la gamma secretasa
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
CA2707722A1 (en) * 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
CA2708300A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
JP2011506460A (ja) * 2007-12-11 2011-03-03 シェーリング コーポレイション γ−セクレターゼモジュレーター
US7923450B2 (en) * 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
CA2736924C (en) 2008-10-09 2016-06-28 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CA2742897A1 (en) * 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
CN102482227A (zh) 2009-07-15 2012-05-30 杨森制药公司 作为γ分泌酶调节剂的取代的三唑和咪唑衍生物

Also Published As

Publication number Publication date
HK1164732A1 (zh) 2012-09-28
AR077434A1 (es) 2011-08-24
EA020322B1 (ru) 2014-10-30
US20110212937A1 (en) 2011-09-01
CA2766515A1 (en) 2011-02-03
AU2010279019A1 (en) 2012-02-09
PT2459197E (pt) 2015-12-18
EP2459197B1 (en) 2015-10-14
US8486952B2 (en) 2013-07-16
WO2011014535A1 (en) 2011-02-03
US20150152089A1 (en) 2015-06-04
PE20120897A1 (es) 2012-07-23
KR20140015126A (ko) 2014-02-06
JP2013500975A (ja) 2013-01-10
CO6430430A2 (es) 2012-04-30
TW201107311A (en) 2011-03-01
JP5680082B2 (ja) 2015-03-04
SI2459197T1 (sl) 2015-12-31
CN102548557B (zh) 2014-12-24
SMT201600011B (it) 2016-02-25
MX2012000973A (es) 2012-03-06
IL217173A0 (en) 2012-02-29
US20150336975A1 (en) 2015-11-26
MY156274A (en) 2016-01-29
ZA201200409B (en) 2013-06-26
HUE026705T2 (en) 2016-07-28
US20130178462A1 (en) 2013-07-11
AU2010279019B2 (en) 2014-12-18
PL2459197T3 (pl) 2016-04-29
CN102548557A (zh) 2012-07-04
IL217173A (en) 2016-05-31
HRP20151133T1 (hr) 2015-11-20
SG177526A1 (en) 2012-02-28
ES2554327T3 (es) 2015-12-18
EA201270225A1 (ru) 2012-07-30
EP2459197A1 (en) 2012-06-06
TWI468402B (zh) 2015-01-11
BR112012002270A2 (pt) 2016-06-14
NZ597701A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
DK2459197T3 (da) Forbindelser til reduktion af beta-amyloidproduktion
US8637525B2 (en) Compounds for the reduction of beta-amyloid production
US8394796B2 (en) Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
EP2379553B1 (en) Bicyclic compounds for the reduction of beta-amyloid production
CA3094700A1 (en) Compounds for treating huntington's disease
US8710061B2 (en) Compounds for the reduction of β-amyloid production
BR112012006807A2 (pt) compostos da fórmula i, composição farmacêutica, composta por composto, método de tratamento de câncer em um mamífero, uso de um composto, kit para tratar um condição mediada por pi3k e processo para a preparação de um composto
EP4055013B1 (en) Wdr5 inhibitors and modulators